Establishment and clinical application of ibrutinib blood concentration assay

HAN Gongwei; ZHANG Teng; ZHAO Yingli; LIU Qinhua; XIA Quan

doi:10.6039/j.issn.1001-0408.2023.22.12

您当前的位置：

首页 >

文章列表页 >

Establishment and clinical application of ibrutinib blood concentration assay

更新时间：2023-11-25

- Establishment and clinical application of ibrutinib blood concentration assay
- ZHONGGUO YAOFANG Vol. 34, Issue 22, Pages: 2756-2759(2023)
- 作者机构：
  
  1.安徽医科大学药学院，合肥　230032
  2.安徽医科大学第一附属医院药剂科，合肥　230022
  3.合肥市第二人民医院药学部，合肥　230012
  4.安徽医科大学第一附属医院血液科，合肥　230022
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.22.12
  CLC： R917
- Published：30 November 2023，
  
  Received：12 May 2023，
  
  Revised：20 October 2023，
扫描看全文
韩功伟,张腾,赵营莉等.伊布替尼血药浓度检测方法的建立及临床应用 ^Δ[J].中国药房,2023,34(22):2756-2759.

HAN Gongwei,ZHANG Teng,ZHAO Yingli,et al.Establishment and clinical application of ibrutinib blood concentration assay[J].ZHONGGUO YAOFANG,2023,34(22):2756-2759.
韩功伟,张腾,赵营莉等.伊布替尼血药浓度检测方法的建立及临床应用 ^Δ[J].中国药房,2023,34(22):2756-2759. DOI： 10.6039/j.issn.1001-0408.2023.22.12.

HAN Gongwei,ZHANG Teng,ZHAO Yingli,et al.Establishment and clinical application of ibrutinib blood concentration assay[J].ZHONGGUO YAOFANG,2023,34(22):2756-2759. DOI： 10.6039/j.issn.1001-0408.2023.22.12.

摘要

目的

建立检测伊布替尼血药浓度的方法并应用于临床。

方法

以泽布替尼为内标，血浆样本以固相萃取柱处理后，采用高效液相色谱（HPLC）法检测伊布替尼的浓度。以Agilent 5 TC-C

（2）为色谱柱，乙腈-0.5%磷酸二氢钾溶液（43∶57，

V/V

）为流动相，流速为1 mL/min，检测波长为260 nm，柱温为40 ℃，进样量为20 μL，运行时间为25 min。采用上述方法测定9例非霍奇金淋巴瘤患者第30天用药后2 h时血浆中伊布替尼的浓度。

结果

伊布替尼检测质量浓度的线性范围为10～500 ng/mL（

＝0.998 9），定量下限为10 ng/mL；批内、批间精密度试验的RSD均不高于12.77%；提取回收率分别为74.80%、97.70%，RSD均小于2.90%；稳定性试验的RSD均小于7.10%。9例患者的血药浓度为15.341～279.628 ng/mL。

结论

所建立的HPLC法简单、快捷，可用于伊布替尼血药浓度的测定。

Abstract

OBJECTIVE

To establish a method to detect the blood concentration of ibrutinib and apply it to the clinic.

METHODS

Using zanubrutinib as internal standard， the concentration of ibrutinib was detected by high performance liquid chromatography （HPLC） after plasma samples were processed by solid-phase extraction. The separation was performed on an Agilent 5 TC-C

（2） column with acetonitrile-0.5% potassium dihydrogen phosphate solution （43∶57，

V/V

） as the mobile phase at a flow rate of 1 mL/min， a detection wavelength of 260 nm， a column temperature of 40 ℃， a sample size of 20 μL， and a run time of 25 min. The concentration of ibrutinib was measured in the plasma of 9 patients with non-Hodgkin’s lymphoma 2 h after drug administration on the 30th day by the above method.

RESULTS

The linear range of the assayed mass concentration of ibrutinib was 10-500 ng/mL （

＝0.998 9）， the lower limit of quantification was 10 ng/mL， and the RSDs of the intra-batch and inter-batch precision tests were not higher than 12.77%. The recoveries of the extraction were 74.80% and 97.70%， with both RSDs＜2.90%， and the RSDs of the stability tests were not higher than 7.10%. The peak plasma concentrations of 9 patients were 15.341-279.628 ng/mL.

CONCLUSIONS

The established HPLC method is simple and rapid， and can be used for the determination of ibrutinib concentration in plasma samples.

关键词

伊布替尼血药浓度非霍奇金淋巴瘤高效液相色谱法

Keywords

blood concentrationnon-Hodgkin’s lymphomahigh performance liquid chromatography

references

ADVANI R H，BUGGY J J，SHARMAN J P，et al. Bruton tyrosine kinase inhibitor ibrutinib（PCI-32765）has signi-ficant activity in patients with relapsed/refractory B-cell malignancies[J]. J Clin Oncol，2013，31（1）：88-94.

BYRD J C，FURMAN R R，COUTRE S E，et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib[J]. Blood，2015，125（16）：2497-2506.

ROOD J J M，JAMALPOOR A，VAN HOPPE S，et al. Extrahepatic metabolism of ibrutinib[J]. Invest New Drugs，2021，39（1）：1-14.

XU R N，WEN J，TANG P F，et al. Functional characte-rization of 22 CYP3A4 protein variants to metabolize ibrutinib in vitro[J]. Basic Clin Pharmacol Toxicol，2018，122（4）：383-387.

KOLLER D，VAITSEKHOVICH V，MBA C，et al. Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring[J]. Talanta，2020，208：120450.

GALLAIS F，YSEBAERT L，DESPAS F，et al. Population pharmacokinetics of ibrutinib and its dihydrodiol metabolite in patients with lymphoid malignancies[J]. Clin Pharmacokinet，2020，59（9）：1171-1183.

位宁，郭进艳，孙文利，等. HPLC-MS/MS法测定血液病患者血浆中伊布替尼血药浓度的方法学研究及临床应用[J]. 中国合理用药探索，2021，18（10）：89-95.

WEI N，GUO J Y，SUN W L，et al. Methodological study and clinical application on the determination of the plasma concentration of ibrutinib in plasma of patients with hematological diseases by HPLC-MS/MS[J]. Chin J Ration Drug Use，2021，18（10）：89-95.

BYRD J C，FURMAN R R，COUTRE S E，et al. Targe-ting BTK with ibrutinib in relapsed chronic lymphocytic leukemia[J]. N Engl J Med，2013，369（1）：32-42.

EZZELDIN E，IQBAL M，HERQASH R N，et al. Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC-MS/MS method and its application to human microsomal metabolic stability study[J]. J Chromatogr B Analyt Technol Biomed Life Sci，2020，1136：121851.

TOBINAI K，OGURA M，ISHIZAWA K，et al. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies[J]. Int J Hematol，2016，103（1）：86-94.

GERTZ M A. Waldenström macroglobulinemia：2023 update on diagnosis，risk stratification，and management[J]. Am J Hematol，2023，98（2）：348-358.

JONG J D，SKEE D，MURPHY J，et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants[J]. Pharmacol Res Perspect，2015，3（4）：e00156.

HAN M M，QIAN J C，YE Z Z，et al. Functional assess-ment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro[J]. Chem Biol Interact，2021，345：109559.

YASU T，MOMO，YASUI H，et al. Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography[J]. Biomed Chromatogr，2019，33（3）：e4435.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on characteristic chromatogram of Chaenomeles sinensis and content determination of 3 flavones

Establishment of HPLC fingerprints for Ardisia crenata， Sophora tonkinensis and their couplet medicines and content determination of 5 chemical components

Study on tissue distribution of curcumin solid lipid nanoparticles in rats

Study on the improvement of quality standard for Jubei mixture

淫桂通便颗粒的质量标准研究

Related Author

ZHU Tianmi

CHEN Shuhe

YAN Jingsong

WANG Xingui

DUAN Yuqing

YANG Xiaoyi

CHEN Yun

SHI Hui

Related Institution

Dept. of Pharmacy， Hubei Provincial Hospital of Traditional Chinese Medicine/the Affiliated Hospital of Hubei University of Chinese Medicine/Hubei Province Academy of Traditional Chinese Medicine

College of Pharmacy， Hubei University of Chinese Medicine

School of Pharmacy， Guizhou University of Traditional Chinese Medicine

Research Center for Application and Development of Medicine and Food Dual-use Resource， Guizhou University of Traditional Chinese Medicine

Guizhou Sanli Pharmaceutical Co.， Ltd.

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰